TriSalus Life Sciences Acquires Dynavax’s SD-101 Oncology Program in Purchase Agreement for up to $250 million in Milestone Payments plus Royalties on Future Net Sales
By: Colorado BioScience Association Date: 08/03/2020
SD-101 is a proprietary investigational, second-generation, Toll-like receptor 9 (TLR9) agonist CpG-C class oligodeoxynucleotide.
TriSalus plans to further develop SD-101 as an oncology therapeutic.
Find out more in the press release.